Quick Answer
Revolution Medicines, Inc. reported R&D Expense of $987.33 million for fiscal year 2025.
Revolution Medicines, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $987.33M | +66.7% |
| 2024 | $592.23M | +40.0% |
| 2023 | $423.14M | +67.2% |
| 2022 | $253.07M | +35.4% |
| 2021 | $186.95M | +41.4% |
| 2020 | $132.25M | +44.1% |
| 2019 | $91.75M | +79.6% |
| 2018 | $51.08M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $262.51M | +73.0% | +17.1% |
| June 30, 2025 | $224.13M | +66.1% | +8.9% |
| March 31, 2025 | $205.75M | +74.3% | +35.6% |
| September 30, 2024 | $151.75M | +40.9% | +12.5% |
| June 30, 2024 | $134.93M | +37.7% | +14.3% |
| March 31, 2024 | $118.02M | +71.2% | +9.5% |
| September 30, 2023 | $107.73M | +55.1% | +10.0% |
| June 30, 2023 | $97.98M | +60.6% | +42.1% |
- Revolution Medicines, Inc. showed an increase of +66.7% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Revolution Medicines, Inc.’s r&d expense has grown by 1832.8% (from $51.08 million to $987.33 million).
- The most recent figure is from Revolution Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: